Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Dana-Farber Cancer Institute · Masaryk Memorial Cancer Institute · +20 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
2,195
total citations
- FWCI
- 130.11
- Percentile
- 100%
- References
- 31
Citations per year
Authors
24- CSCharles S. FuchsCorresponding
Dana-Farber Cancer Institute
- JTJiří Tomášek
Masaryk Memorial Cancer Institute
- CJCho Jae Yong
Yonsei University, Gangnam Severance Hospital
- FDFilip Dumitru
County Hospital
- RPRodolfo Passalacqua
Istituti Ospitalieri di Cremona
Topics & keywords
Topics
Keywords
- Ramucirumab
- Medicine
- Internal medicine
- Hazard ratio
- Placebo
- Clinical endpoint
- Gastroenterology
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.